The Centers for Medicare & Medicaid say they plan to keep the same reimbursement rate for treatment with Abiomed's Impella heart pump, sending ABMD shares up on Wall Street.
Abiomed (NSDQ:ABMD) said today that the Centers for Medicare & Medicaid Services plan to maintain the reimbursement rate for treatment with its Impella heart pump when new rates go into effect this fall.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1h26rI4
Cap comentari:
Publica un comentari a l'entrada